A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines
Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointest...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2019-10, Vol.106 (4), p.803-809 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 809 |
|---|---|
| container_issue | 4 |
| container_start_page | 803 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 106 |
| creator | Hirakawa, Akihiro Sudo, Kazuki Yonemori, Kan Sadachi, Ryo Kinoshita, Fumie Kobayashi, Yumiko Okuma, Hitomi S. Kawachi, Asuka Tamura, Kenji Fujiwara, Yasuhiro Rubinstein, Larry Takebe, Naoko |
| description | Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointestinal disorders, skin and subcutaneous tissue disorders, and cardiac disorders, and compared their longitudinal toxicity data among four types of cancer therapeutics. In total, 28,235 patients who were enrolled into 772 early‐phase trials to evaluate the monotherapies of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, or cancer vaccines were evaluated. For each toxicity, we compared their grade prevalence, mean grade at each cycle, and time to toxicity occurrence and identified the potential underlying similarities and differences of longitudinal toxicities among the four cancer treatment types. Our results will further help in understanding the profile of cancer therapeutic toxicities and their impact on oncology treatment in practice. |
| doi_str_mv | 10.1002/cpt.1442 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2200783373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2200783373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3872-e0e063958a0094bfe518769e0f30fcef7640539145a3efbe05f7b7b5aa5b68d73</originalsourceid><addsrcrecordid>eNp1kM1OwzAQhC0EgvIj8QTIRw6kOHEcJ8cq_FUqAonANXKcdWWUxMV2gDwDL00KFE6cVrPz7Ug7CB2HZBoSEp3LlZ-GcRxtoUnIaBQkjLJtNCGEZEEW0WQP7Tv3PMo4S9NdtEdJFvGYZhP0McO5aVfCCq9fAT_4vh6wUXhhuqUehe5EgwvzrqX2Gtzaygdv_HqDL2y_dGf41jQg-0bYZsCFsEvwUOPZEjo_mvO27TvTmnoEvLHD5kh0Nc5FJ8HiJyGl7sAdoh0lGgdHP_MAPV5dFvlNsLi7nuezRSBpyqMACJCEZiwV43txpYCFKU8yIIoSJUHxJCaMZmHMBAVVAWGKV7xiQrAqSWtOD9Dpd-7KmpcenC9b7SQ0jejA9K6MIkJ4Simnf6i0xjkLqlxZ3Qo7lCEp19WXY_XluvoRPflJ7asW6l9w0_UIBN_Am25g-DeozO-Lr8BP8T2O2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2200783373</pqid></control><display><type>article</type><title>A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Hirakawa, Akihiro ; Sudo, Kazuki ; Yonemori, Kan ; Sadachi, Ryo ; Kinoshita, Fumie ; Kobayashi, Yumiko ; Okuma, Hitomi S. ; Kawachi, Asuka ; Tamura, Kenji ; Fujiwara, Yasuhiro ; Rubinstein, Larry ; Takebe, Naoko</creator><creatorcontrib>Hirakawa, Akihiro ; Sudo, Kazuki ; Yonemori, Kan ; Sadachi, Ryo ; Kinoshita, Fumie ; Kobayashi, Yumiko ; Okuma, Hitomi S. ; Kawachi, Asuka ; Tamura, Kenji ; Fujiwara, Yasuhiro ; Rubinstein, Larry ; Takebe, Naoko</creatorcontrib><description>Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointestinal disorders, skin and subcutaneous tissue disorders, and cardiac disorders, and compared their longitudinal toxicity data among four types of cancer therapeutics. In total, 28,235 patients who were enrolled into 772 early‐phase trials to evaluate the monotherapies of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, or cancer vaccines were evaluated. For each toxicity, we compared their grade prevalence, mean grade at each cycle, and time to toxicity occurrence and identified the potential underlying similarities and differences of longitudinal toxicities among the four cancer treatment types. Our results will further help in understanding the profile of cancer therapeutic toxicities and their impact on oncology treatment in practice.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.1442</identifier><identifier>PMID: 30927439</identifier><language>eng</language><publisher>United States</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - classification ; Cancer Vaccines - adverse effects ; Clinical Trials as Topic ; Cytotoxins - adverse effects ; Drug-Related Side Effects and Adverse Reactions - classification ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - etiology ; Female ; Humans ; Immunologic Factors - adverse effects ; Long Term Adverse Effects - chemically induced ; Long Term Adverse Effects - classification ; Long Term Adverse Effects - epidemiology ; Male ; Middle Aged ; Molecular Targeted Therapy - adverse effects ; Neoplasms - drug therapy ; Prevalence ; Severity of Illness Index</subject><ispartof>Clinical pharmacology and therapeutics, 2019-10, Vol.106 (4), p.803-809</ispartof><rights>2019 The Authors © 2019 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3872-e0e063958a0094bfe518769e0f30fcef7640539145a3efbe05f7b7b5aa5b68d73</citedby><cites>FETCH-LOGICAL-c3872-e0e063958a0094bfe518769e0f30fcef7640539145a3efbe05f7b7b5aa5b68d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.1442$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.1442$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30927439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirakawa, Akihiro</creatorcontrib><creatorcontrib>Sudo, Kazuki</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Sadachi, Ryo</creatorcontrib><creatorcontrib>Kinoshita, Fumie</creatorcontrib><creatorcontrib>Kobayashi, Yumiko</creatorcontrib><creatorcontrib>Okuma, Hitomi S.</creatorcontrib><creatorcontrib>Kawachi, Asuka</creatorcontrib><creatorcontrib>Tamura, Kenji</creatorcontrib><creatorcontrib>Fujiwara, Yasuhiro</creatorcontrib><creatorcontrib>Rubinstein, Larry</creatorcontrib><creatorcontrib>Takebe, Naoko</creatorcontrib><title>A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointestinal disorders, skin and subcutaneous tissue disorders, and cardiac disorders, and compared their longitudinal toxicity data among four types of cancer therapeutics. In total, 28,235 patients who were enrolled into 772 early‐phase trials to evaluate the monotherapies of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, or cancer vaccines were evaluated. For each toxicity, we compared their grade prevalence, mean grade at each cycle, and time to toxicity occurrence and identified the potential underlying similarities and differences of longitudinal toxicities among the four cancer treatment types. Our results will further help in understanding the profile of cancer therapeutic toxicities and their impact on oncology treatment in practice.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - classification</subject><subject>Cancer Vaccines - adverse effects</subject><subject>Clinical Trials as Topic</subject><subject>Cytotoxins - adverse effects</subject><subject>Drug-Related Side Effects and Adverse Reactions - classification</subject><subject>Drug-Related Side Effects and Adverse Reactions - epidemiology</subject><subject>Drug-Related Side Effects and Adverse Reactions - etiology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - adverse effects</subject><subject>Long Term Adverse Effects - chemically induced</subject><subject>Long Term Adverse Effects - classification</subject><subject>Long Term Adverse Effects - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy - adverse effects</subject><subject>Neoplasms - drug therapy</subject><subject>Prevalence</subject><subject>Severity of Illness Index</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1OwzAQhC0EgvIj8QTIRw6kOHEcJ8cq_FUqAonANXKcdWWUxMV2gDwDL00KFE6cVrPz7Ug7CB2HZBoSEp3LlZ-GcRxtoUnIaBQkjLJtNCGEZEEW0WQP7Tv3PMo4S9NdtEdJFvGYZhP0McO5aVfCCq9fAT_4vh6wUXhhuqUehe5EgwvzrqX2Gtzaygdv_HqDL2y_dGf41jQg-0bYZsCFsEvwUOPZEjo_mvO27TvTmnoEvLHD5kh0Nc5FJ8HiJyGl7sAdoh0lGgdHP_MAPV5dFvlNsLi7nuezRSBpyqMACJCEZiwV43txpYCFKU8yIIoSJUHxJCaMZmHMBAVVAWGKV7xiQrAqSWtOD9Dpd-7KmpcenC9b7SQ0jejA9K6MIkJ4Simnf6i0xjkLqlxZ3Qo7lCEp19WXY_XluvoRPflJ7asW6l9w0_UIBN_Am25g-DeozO-Lr8BP8T2O2Q</recordid><startdate>201910</startdate><enddate>201910</enddate><creator>Hirakawa, Akihiro</creator><creator>Sudo, Kazuki</creator><creator>Yonemori, Kan</creator><creator>Sadachi, Ryo</creator><creator>Kinoshita, Fumie</creator><creator>Kobayashi, Yumiko</creator><creator>Okuma, Hitomi S.</creator><creator>Kawachi, Asuka</creator><creator>Tamura, Kenji</creator><creator>Fujiwara, Yasuhiro</creator><creator>Rubinstein, Larry</creator><creator>Takebe, Naoko</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201910</creationdate><title>A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines</title><author>Hirakawa, Akihiro ; Sudo, Kazuki ; Yonemori, Kan ; Sadachi, Ryo ; Kinoshita, Fumie ; Kobayashi, Yumiko ; Okuma, Hitomi S. ; Kawachi, Asuka ; Tamura, Kenji ; Fujiwara, Yasuhiro ; Rubinstein, Larry ; Takebe, Naoko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3872-e0e063958a0094bfe518769e0f30fcef7640539145a3efbe05f7b7b5aa5b68d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - classification</topic><topic>Cancer Vaccines - adverse effects</topic><topic>Clinical Trials as Topic</topic><topic>Cytotoxins - adverse effects</topic><topic>Drug-Related Side Effects and Adverse Reactions - classification</topic><topic>Drug-Related Side Effects and Adverse Reactions - epidemiology</topic><topic>Drug-Related Side Effects and Adverse Reactions - etiology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - adverse effects</topic><topic>Long Term Adverse Effects - chemically induced</topic><topic>Long Term Adverse Effects - classification</topic><topic>Long Term Adverse Effects - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy - adverse effects</topic><topic>Neoplasms - drug therapy</topic><topic>Prevalence</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirakawa, Akihiro</creatorcontrib><creatorcontrib>Sudo, Kazuki</creatorcontrib><creatorcontrib>Yonemori, Kan</creatorcontrib><creatorcontrib>Sadachi, Ryo</creatorcontrib><creatorcontrib>Kinoshita, Fumie</creatorcontrib><creatorcontrib>Kobayashi, Yumiko</creatorcontrib><creatorcontrib>Okuma, Hitomi S.</creatorcontrib><creatorcontrib>Kawachi, Asuka</creatorcontrib><creatorcontrib>Tamura, Kenji</creatorcontrib><creatorcontrib>Fujiwara, Yasuhiro</creatorcontrib><creatorcontrib>Rubinstein, Larry</creatorcontrib><creatorcontrib>Takebe, Naoko</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirakawa, Akihiro</au><au>Sudo, Kazuki</au><au>Yonemori, Kan</au><au>Sadachi, Ryo</au><au>Kinoshita, Fumie</au><au>Kobayashi, Yumiko</au><au>Okuma, Hitomi S.</au><au>Kawachi, Asuka</au><au>Tamura, Kenji</au><au>Fujiwara, Yasuhiro</au><au>Rubinstein, Larry</au><au>Takebe, Naoko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2019-10</date><risdate>2019</risdate><volume>106</volume><issue>4</issue><spage>803</spage><epage>809</epage><pages>803-809</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Little is known about the toxicity of various therapeutics for cancer over time because randomized controlled clinical trials that compare several treatments are limited. In this study, we focused on the toxicities most frequently discussed, which are investigations (lab abnormalities), gastrointestinal disorders, skin and subcutaneous tissue disorders, and cardiac disorders, and compared their longitudinal toxicity data among four types of cancer therapeutics. In total, 28,235 patients who were enrolled into 772 early‐phase trials to evaluate the monotherapies of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, or cancer vaccines were evaluated. For each toxicity, we compared their grade prevalence, mean grade at each cycle, and time to toxicity occurrence and identified the potential underlying similarities and differences of longitudinal toxicities among the four cancer treatment types. Our results will further help in understanding the profile of cancer therapeutic toxicities and their impact on oncology treatment in practice.</abstract><cop>United States</cop><pmid>30927439</pmid><doi>10.1002/cpt.1442</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2019-10, Vol.106 (4), p.803-809 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2200783373 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antineoplastic Agents - adverse effects Antineoplastic Agents - classification Cancer Vaccines - adverse effects Clinical Trials as Topic Cytotoxins - adverse effects Drug-Related Side Effects and Adverse Reactions - classification Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Female Humans Immunologic Factors - adverse effects Long Term Adverse Effects - chemically induced Long Term Adverse Effects - classification Long Term Adverse Effects - epidemiology Male Middle Aged Molecular Targeted Therapy - adverse effects Neoplasms - drug therapy Prevalence Severity of Illness Index |
| title | A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A08%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparative%20Study%20of%20Longitudinal%20Toxicities%20of%20Cytotoxic%20Drugs,%20Molecularly%20Targeted%20Agents,%20Immunomodulatory%20Drugs,%20and%20Cancer%20Vaccines&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Hirakawa,%20Akihiro&rft.date=2019-10&rft.volume=106&rft.issue=4&rft.spage=803&rft.epage=809&rft.pages=803-809&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.1442&rft_dat=%3Cproquest_cross%3E2200783373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2200783373&rft_id=info:pmid/30927439&rfr_iscdi=true |